<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE topic PUBLIC "-//IFRS//DTD DITA Topic//EN" "../../../DocTypes/com.ifrs.doctype/dtd/ifrsTopic.dtd"><topic id="IFRS03_IE_TOC"><title/><body><ol reference_label="paragraph" toc_label="contents" type="toc"><li outputclass="primary"><ph outputclass="standard_ref"><ph outputclass="standard_number">IFRS 3</ph> <ph outputclass="standard_title">BUSINESS COMBINATIONS </ph></ph> ILLUSTRATIVE EXAMPLES</li><li><xref base="F15836617" href="IFRS03_gIE1-IE2.dita#IFRS03_gIE1-IE2" id="IFRS03_X0551">REVERSE ACQUISITIONS</xref>         <ol type="toc"><li><xref base="F15836649" href="IFRS03_gIE4-IE5.dita#IFRS03_gIE4-IE5" id="IFRS03_X0552">Calculating the fair value of the consideration transferred</xref></li><li><xref base="F15836650" href="IFRS03_gIE6-IE6.dita#IFRS03_gIE6-IE6" id="IFRS03_X0553">Measuring goodwill</xref></li><li><xref base="F15836651" href="IFRS03_gIE7-IE8.dita#IFRS03_gIE7-IE8" id="IFRS03_X0554">Consolidated statement of financial position at 30 September 20X6</xref></li><li><xref base="F15836652" href="IFRS03_gIE9-IE10.dita#IFRS03_gIE9-IE10" id="IFRS03_X0555">Earnings per share</xref></li><li><xref base="F15836653" href="IFRS03_gIE11-IE15.dita#IFRS03_gIE11-IE15" id="IFRS03_X0556">Non-controlling interest</xref></li></ol>       </li><li><xref base="F15836654" href="IFRS03_gIE16-IE44.dita#IFRS03_gIE16-IE44" id="IFRS03_X0557">IDENTIFIABLE INTANGIBLE ASSETS</xref>         <ol type="toc"><li><xref base="F15836655" href="IFRS03_gIE18-IE22.dita#IFRS03_gIE18-IE22" id="IFRS03_X0558">Marketing-related intangible assets</xref></li><li><xref base="F15836656" href="IFRS03_gIE23-IE31.dita#IFRS03_gIE23-IE31" id="IFRS03_X0559">Customer-related intangible assets</xref></li><li><xref base="F15836657" href="IFRS03_gIE32-IE33.dita#IFRS03_gIE32-IE33" id="IFRS03_X0560">Artistic-related intangible assets</xref></li><li><xref base="F15836658" href="IFRS03_gIE34-IE38.dita#IFRS03_gIE34-IE38" id="IFRS03_X0561">Contract-based intangible assets</xref></li><li><xref base="F15836689" href="IFRS03_gIE39-IE44.dita#IFRS03_gIE39-IE44" id="IFRS03_X0562">Technology-based intangible assets</xref></li></ol>       </li><li><xref base="F15836690" href="IFRS03_gIE44A-IE44J.dita#IFRS03_gIE44A-IE44J" id="IFRS03_X0563">MEASUREMENT OF NON-CONTROLLING INTEREST (NCI)</xref>         <ol type="toc"><li><xref base="F15836691" href="IFRS03_gIE44B-IE44E.dita#IFRS03_gIE44B-IE44E" id="IFRS03_X0564">Measurement of NCI including preference shares</xref></li><li><xref base="F15836692" href="IFRS03_gIE44F-IE44G.dita#IFRS03_gIE44F-IE44G" id="IFRS03_X0565">First variation</xref></li><li><xref base="F15836693" href="IFRS03_gIE44H-IE44J.dita#IFRS03_gIE44H-IE44J" id="IFRS03_X0566">Second variation</xref></li></ol>       </li><li><xref base="F15836694" href="IFRS03_gIE45-IE49.dita#IFRS03_gIE45-IE49" id="IFRS03_X0567">GAIN ON A BARGAIN PURCHASE</xref></li><li><xref base="F15836695" href="IFRS03_gIE50-IE53.dita#IFRS03_gIE50-IE53" id="IFRS03_X0568">MEASUREMENT PERIOD</xref></li><li><xref base="F35713783" href="IFRS03_gIE54-IE71.dita#IFRS03_gIE54-IE71/IFRS03_gIE54-IE71_TI" id="IFRS03_X0569">DETERMINING WHAT IS PART OF THE BUSINESS COMBINATION TRANSACTION</xref>         <ol type="toc"><li><xref base="F15836697" href="IFRS03_gIE54-IE57.dita#IFRS03_gIE54-IE57" id="IFRS03_X0570">Settlement of a pre-existing relationship</xref></li><li><xref base="F15836729" href="IFRS03_gIE58-IE60.dita#IFRS03_gIE58-IE60" id="IFRS03_X0571">Contingent payments to employees</xref></li><li><xref base="F15836730" href="IFRS03_gIE61-IE71.dita#IFRS03_gIE61-IE71" id="IFRS03_X0572">Replacement awards</xref></li></ol>       </li><li><xref base="F15836731" href="IFRS03_gIE72-IE72.dita#IFRS03_gIE72-IE72" id="IFRS03_X0573">DISCLOSURE REQUIREMENTS</xref></li><li><xref href="IFRS03_gIE73-IE123.dita" scope="local">Definition of a business</xref>         <ol type="toc"><li><xref href="IFRS03_gIE74-IE86.dita" scope="local">Example A—acquisition of real estate</xref></li><li><xref href="IFRS03_gIE87-IE92.dita" scope="local">Example B—acquisition of a drug candidate</xref></li><li><xref href="IFRS03_gIE93-IE97.dita" scope="local">Example C—acquisition of a biotech entity</xref></li><li><xref href="IFRS03_gIE98-IE100.dita" scope="local">Example D—acquisition of a television station</xref></li><li><xref href="IFRS03_gIE101-IE103.dita" scope="local">Example E—acquisition of a closed manufacturing facility</xref></li><li><xref href="IFRS03_gIE104-IE106.dita" scope="local">Example F—licence of distribution rights</xref></li><li><xref href="IFRS03_gIE107-IE109.dita" scope="local">Example G—acquisition of brands</xref></li><li><xref href="IFRS03_gIE110-IE117.dita" scope="local">Example H—acquisition of loan portfolio</xref></li><li><xref href="IFRS03_gIE118-IE123.dita" scope="local">Example I—determining the fair value of the gross assets acquired</xref></li></ol>       </li><li outputclass="keep_with_next"><xref base="F15836616" href="IFRS03_IE_APP.dita#IFRS03_IE_APP" id="IFRS03_X0575">APPENDIX</xref>         <ol type="toc"><li><xref base="F15836615" href="IFRS03_IE_APP.dita#IFRS03_IE_APP" id="IFRS03_X0576">Amendments to guidance on other IFRSs</xref></li></ol>       </li></ol></body></topic>